**BREAKING: MATTHEW PERRY’S “ACCIDENTAL” KETAMINE OVERDOSE—WHO REALLY PROFITS?**
In a twist that’s raising more than a few eyebrows, new details have emerged about Matthew Perry’s alleged “accidental” ketamine overdose. While the mainstream media is rushing to label it a tragic relapse, skeptics are asking: *Who benefits from this narrative?*
Insiders whisper that the former "Friends" star was pushing for federal lobbying against Big Pharma’s monopoly on mental health treatments—specifically alternative therapies like clinical ketamine. Just weeks before his death, Perry quietly met with lawmakers to discuss expanding access to low-cost, non-patented treatments, threatening the bottom line of pharmaceutical giants.
Now, with his sudden passing, those efforts have ground to a halt. And guess which companies just saw their stock prices surge? You got it—the very same firms that manufacture expensive, patented antidepressants.
Coincidence? Or a convenient script rewrite, Hollywood-style?
Stay skeptical. Follow the money.